In case you’ve missed it, Philly docs have scored some big headlines recently. After nearly thirty years in development at the University of Pennsylvania, a novel cancer treatment that many are calling the most promising yet could be just weeks away from hitting the market.
Back in July, the gene therapy known as CAR T, named for the chimeric antigen receptor T-cells it utilizes, was unanimously recommended for approval by an FDA advisory committee. The recommendation is as close to a predictor of approval as a treatment can get. The long path of immunotherapy research and trials – headed by Dr. Carl June – that led to the submission for FDA approval was recently chronicled in a Time feature titled “Inside Cancer’s Newest Miracle Cure.” After years of trials with an erratic range of results, June’s major breakthrough came when he identified a biological marker unique to cancerous leukemia cells that allowed him to tweak his treatment to make it a little more targeted. Read more »